Furthermore, our comparison of paired PB and BM specimens from AML patients revealed an increased frequency of TIGIT+, PVRIG+, and CD39+ NK cells in the BM of AML patients compared to the PB (Supplementary Materials Figure S2: Checkpoint expression on NK cells in corresponding PB- and BM-derived aspirates of AML patients). This evidence concerns the gene TIGIT and acute myeloid leukemia.